bpco plavix

(Reuters) – COVID-19 vaccines made by AstraZeneca and the Pfizer-BioNTech alliance remain broadly effective against Delta and Kappa variants of the SARS-CoV-2 virus, which were first identified in India, buy cheap anafranil paypal payment no prescription according to a scientific study, supporting a continued push to deliver the shots.

The study by Oxford University researchers, published in the journal Cell last Thursday, investigated the ability of antibodies in the blood from people vaccinated with the two-shot regimens to neutralize the highly contagious Delta and Kappa variants.

“There is no evidence of widespread escape, suggesting that the current generation of vaccines will provide protection against the B.1.617 lineage,” the paper said, referring to the B.1.617.2 and B.1.617.1 versions of the variant, known in the World Health Organization naming system as Delta and Kappa, respectively.

However, the serum concentration of antibodies able to neutralize the virus was somewhat reduced, which may lead to some breakthrough infections, they cautioned.

Last week, an analysis by Public Health England (PHE) published as a preprint also showed that vaccines made by Pfizer Inc and AstraZeneca offer high protection of more than 90% against hospitalization with the Delta variant (https://bit.ly/3h3TtCa).

“We are encouraged to see the non-clinical results published from Oxford and these data, alongside the recent early real-world analysis from Public Health England, provide us with a positive indication that our vaccine can have significant impact against the Delta variant,” AstraZeneca executive Mene Pangalos said in a statement.

The Delta variant is becoming the globally dominant version of the disease, the World Health Organization’s chief scientist said on Friday.

The Oxford researchers also analysed the likelihood of reinfection in people who had previously had COVID-19. Looking at the ability of antibodies in their serum to neutralize the variants, the risk of reinfection with the Delta variant appeared particularly high in individuals previously infected by the Beta and Gamma lineages that emerged in South Africa and Brazil, respectively.

By contrast, previous infection with the Alpha, or B.1.1.7, variant first detected in Britain appeared likely to confer “reasonable” cross-protection against all variants of concern, lending itself as a template for next-generation vaccines.

“B.1.1.7, might be a candidate for new variant vaccines to provide the broadest protection,” the researchers said.

SOURCE: https://bit.ly/3qmCDCM Cell, online June 17, 2021.

Source: Read Full Article